Key Developments and Trends Steering the Liquid Biopsy Market Forward: Advancements In Liquid Biopsy Products Drive Innovation In Cancer Diagnosis And Treatment
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Liquid Biopsy Market Expected to Grow Between 2025 And 2029?
The size of the liquid biopsy market has experienced quick expansion in the recent past. The market which stood at $1.25 billion in 2024, is projected to rise to $1.46 billion in 2025, representing a compound annual growth rate (CAGR) of 16.1%. The growth recorded in the historic period is due to developments in cancer research, non-invasive procedures, personalized medicine, regulatory approvals, and the capacity for early cancer detection.
The market size for liquid biopsy is projected to witness an accelerated expansion in the forthcoming years, scaling to$2.7 billion in 2029 with a compound annual growth rate (CAGR) of 16.7%. The rise in this forecast period can be associated with the wider applications it offers, cancer surveillance methods, novel technologies, partner diagnostics, and discovery of biomarkers. Predominant trends during the forecast period encompass cancer detection and supervision, therapeutic observation, monitoring of minimum residual disease (mrd), and the use of liquid biopsy in non-oncological applications.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theLiquid Biopsy Market?
The liquid biopsy market is experiencing growth due to government funding targeted at improving cancer detection techniques. These funds are pivotal in aiding research efforts focused on medicine discovery, diagnosing, and treating diseases, including cancer. For example, in 2022, the National Institute of Health (NIH), a medical research agency located in the U.S., received a $46.6 billion fund, out of which $6.9 billion was allocated to the National Cancer Institute (NCI), an American cancer research organization, to support the progress of cancer research. Consequently, government funding has a positive effect on the advancement of the liquid biopsy market.
Which Segments in the Liquid Biopsy Offer the Most Growth?
The liquid biopsymarket covered in this report is segmented –
1) By Product: Assays Kits; Instruments; Services
2) By Clinical Application: Early Cancer Screening; Therapy Selection; Treatment Monitoring; Recurrence Monitoring Orthopedics
3) By End User: Reference Laboratories; Hospitals and Physician Laboratories; Academic and Research Centers
Subsegments:
1) By Assays Kits: cfDNA Assays; ctDNA Assays; Exosome-based Assays; RNA-based Assays; Protein-based Assays
2) By Instruments: PCR Instruments; Next-Generation Sequencing (NGS) Instruments; Microarray Instruments; Mass Spectrometry Instruments
3) By Services: Testing Services; Data Analysis Services; Laboratory Services; Custom Assay Development Services
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=2815&type=smp
What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theLiquid Biopsy Market?# Market?
North America was the largest region in the liquid biopsy market in 2024. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Current Market Growth and Trends in the Liquid Biopsy Industry?
Firms are swiftly adapting new market dynamics and prioritizing the launch of cutting-edge products to fulfill the growing demand for liquid biopsy products and services, enhance their income, and secure a competitive advantage over their peers. In June 2023, for example, Laboratory Corporation of America Holdings, a healthcare firm based in the US, unveiled a liquid biopsy test named Labcorp Plasma Focus. This test is designed to detect cancer-linked biomarkers in individuals with advanced or metastatic solid tumors. It surveys the cell-free DNA (cfDNA) in a patient’s blood sample to build a genomic profile of their tumor, enabling oncologists to improve patient healthcare management through the formation of personalized, highly targeted therapy strategies. Therefore, companies are committing resources to the development of superior products in the liquid biopsy market.
View the full report here:
https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report
What Are the Key Elements That Define the Liquid Biopsy Market?
A liquid biopsy is a quick and painless substitute for surgical biopsies that allows medical professionals to learn a lot about a tumor from a small blood sample. A liquid biopsy is a diagnostic test performed on blood to detect the presence of any cancerous cells in the blood. It is used to detect cancer at an early stage.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2815
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
